ES2058293T3 - 2,3-dihidroergolinas para mejorar la funcion serotonergica. - Google Patents

2,3-dihidroergolinas para mejorar la funcion serotonergica.

Info

Publication number
ES2058293T3
ES2058293T3 ES88307751T ES88307751T ES2058293T3 ES 2058293 T3 ES2058293 T3 ES 2058293T3 ES 88307751 T ES88307751 T ES 88307751T ES 88307751 T ES88307751 T ES 88307751T ES 2058293 T3 ES2058293 T3 ES 2058293T3
Authority
ES
Spain
Prior art keywords
dihidroergolinas
improve
serotonergic function
dihydroergolines
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307751T
Other languages
English (en)
Inventor
Leander Merritt
John Stanley Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2058293T3 publication Critical patent/ES2058293T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REVELA UN METODO TERAPEUTICO QUE EMPLEA 2,3 DIHIDROERGOLINAS. DICHO METODO POTENCIA LA FUNCION SEROTANERGICA EN EL SISTEMA NERVIOSO DE MAMIFEROS NECESITADOS DE ELLA, ENCONTRANDO ASI APLICACION EN MANIFESTACIONES FISIOLOGICAS MEDIADAS POR SEROTONINA QUE INCLUYEN LA MEMORIA, DEPRESION, ANSIEDAD, DOLOR Y APETITO. TAMBIEN SE DESCRIBEN COMPUESTOS FARMACEUTICOS QUE CONTIENEN DICHAS 2,3 - DIHIDROERGOLINAS EN CONJUNCION CON DILUYENTES Y PORTADORES FARMACEUTICAMENTE ADMITIDOS.
ES88307751T 1987-08-31 1988-08-22 2,3-dihidroergolinas para mejorar la funcion serotonergica. Expired - Lifetime ES2058293T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/091,462 US4798834A (en) 1987-08-31 1987-08-31 Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement

Publications (1)

Publication Number Publication Date
ES2058293T3 true ES2058293T3 (es) 1994-11-01

Family

ID=22227911

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307751T Expired - Lifetime ES2058293T3 (es) 1987-08-31 1988-08-22 2,3-dihidroergolinas para mejorar la funcion serotonergica.

Country Status (6)

Country Link
US (1) US4798834A (es)
EP (1) EP0306191B1 (es)
JP (1) JPS6468322A (es)
AT (1) ATE111354T1 (es)
DE (1) DE3851497T2 (es)
ES (1) ES2058293T3 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674875A (en) * 1993-05-04 1997-10-07 Eli Lilly And Company Method of blocking human 5-hydroxytryptamine-2 receptors
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
BRPI0516217A (pt) * 2004-09-28 2008-08-26 Allergan Inc compostos de 4-benzil-1,3-diidro-imidazol-2-tionas não-substituìdos e substituìdos que atuam como agonistas especìficos ou seletivos alfa2-adrenérgicos e métodos de utilização dos mesmos
WO2018076019A1 (en) * 2016-10-21 2018-04-26 Far Biotech, Inc. Ergot derivative compounds and their use in african sleeping sickness and related disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH344731A (de) * 1956-05-18 1960-02-29 Sandoz Ag Verfahren zur Herstellung von neuen, am Indolstickstoff alkylierten Derivaten der Lysergsäure-Reihe
US3580916A (en) * 1969-02-20 1971-05-25 Lilly Co Eli Hydroxyesters of hexa- and octahydroindoloquinolines
IE41533B1 (en) * 1974-03-14 1980-01-30 Sandoz Ltd Thiomethyl ergolene derivatives
US3992385A (en) * 1975-01-20 1976-11-16 Eli Lilly And Company 2,3-Dihydroergolines
DE2656344A1 (de) * 1975-12-23 1977-07-07 Sandoz Ag Ergolinderivate, ihre verwendung und herstellung
CH628049A5 (en) * 1977-03-25 1982-02-15 Sandoz Ag Process for the preparation of ergolene derivatives
US4166182A (en) * 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
US4201862A (en) * 1979-03-16 1980-05-06 Eli Lilly And Company 2-Azaergolines and 2-aza-8(or 9)-ergolenes
CH649998A5 (de) * 1982-08-09 1985-06-28 Sandoz Ag Ergolinderivate, ein verfahren zu ihrer herstellung und heilmittel, enthaltend diese ergolinderivate als wirkstoff.
DE3411981A1 (de) * 1984-03-28 1985-10-10 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 2.3-dihydroergolinen
DE3445784A1 (de) * 1984-12-13 1986-06-26 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von ergolin-derivaten

Also Published As

Publication number Publication date
DE3851497T2 (de) 1995-02-16
DE3851497D1 (de) 1994-10-20
EP0306191B1 (en) 1994-09-14
US4798834A (en) 1989-01-17
EP0306191A2 (en) 1989-03-08
JPS6468322A (en) 1989-03-14
EP0306191A3 (en) 1991-11-06
ATE111354T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
MX9203543A (es) Medicamento.
IT1197038B (it) Composizione farmaceutica ad attivita' analgesica
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
BG47033A3 (en) Method for preparing of derivatives of imidazolamine
NO169998C (no) Kjerne eller grunnmasse for farmasoeytiske preparater med regulert avgivelse for oral administrering
DE3674906D1 (de) Selbstklemmende medizinische prothese und ihre herstellung.
DE3671367D1 (de) Arzneistoffadsorbate und deren herstellung.
ES2058293T3 (es) 2,3-dihidroergolinas para mejorar la funcion serotonergica.
EG19912A (en) The use of the active substance azelastine in combatting psoriasis disorders and inflammatory disorders
EP0276536A3 (en) Use of buspirone for the improvement of short term memory
IT8519885A0 (it) Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
ATE113207T1 (de) Benzamid gegen kognitive erkrankungen.
FR2623806B1 (fr) Esters d'acides 3,6-dihydro-1,5(2h)-pyrimidinecarboxyliques a action therapeutique
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
LV10250A (lv) Jauni antiaritmijas lidzekli panemiens to iegusanai arstniecibas lidzeklis pielietojums
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
IT8848251A0 (it) Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
DE58904383D1 (de) Feste arzneiform, enthaltend gallopamil.
DE69030665D1 (de) (1,2n) und (3,2n)-karbozyklische-2-amino-tetralinderivate
FR2624008B1 (fr) Prothese extra-thoracique d'assistance ventilatoire moulable par depression
DE3784048D1 (de) 5-hydroxymethyl-derivate des 2-oxazolidinons, deren herstellung und deren anwendung in der therapie.
ES2094757T3 (es) Un factor megacariocitopoyetico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 306191

Country of ref document: ES